Mallinckrodt

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. The company’s Endo Pharmaceuticals segment offers branded prescription products,

Silence Therapeutics is a biotechnology company based in London, focused on the discovery, development, and delivery of innovative RNA therapeutics for various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. The company specializes in designing short interfering RNA (siRNA) molecules that activate the RNA interference (RNAi) pathway to selectively degrade target messenger RNAs. Its product pipeline includes SLN124, aimed at treating iron overload disorders, SLN360, which targets cardiovascular diseases associated with elevated lipoprotein levels, and SLN500 for complement-mediated diseases. Silence Therapeutics has established strategic collaborations with AstraZeneca to develop small interfering RNA therapeutics for a range of diseases, and with Genomics England Limited. The company was previously known as SR Pharma before rebranding in 2007.

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing specialized medicines targeting significant unmet medical needs worldwide. The company markets two primary products: AMITIZA, which addresses chronic and idiopathic constipation as well as opioid-induced constipation, and RESCULA. Sucampo is advancing a late-stage pipeline that includes VTS-270, a treatment for Niemann-Pick Disease Type C-1, which is currently in a pivotal Phase 2/3 clinical trial and has received orphan designation in both the U.S. and Europe. Additionally, Sucampo holds an option for North American rights to CPP1-x/sulindac, a drug in Phase 3 development for familial adenomatous polyposis, also granted orphan drug designation in the U.S. Headquartered in Rockville, Maryland, Sucampo operates globally with a presence in Japan and Switzerland.

Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for patients suffering from acute and chronic liver diseases, addressing a significant unmet medical need. The company's lead product, OCR-002, functions as an ammonia scavenger and is being investigated in both intravenous and oral formulations to treat hyperammonemia. Recently, Ocera completed a Phase 2b clinical trial named STOP-HE, which assessed the safety and efficacy of intravenously administered OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. Ocera is currently preparing for a meeting with the FDA to discuss the intravenous program and explore potential development pathways for its therapeutics.

InfaCare Pharmaceutical specializes in developing pharmaceuticals tailored for neonatal and pediatric patients, focusing on addressing unmet medical needs in these vulnerable populations. Their portfolio includes treatments for autoimmune and rare diseases across several specialty areas, such as neurology, rheumatology, nephrology, pulmonology, and immunotherapy. A notable product is a heme oxygenase inhibitor designed for the treatment of neonatal hyperbilirubinemia, which can be administered as a single intramuscular injection to both term and pre-term newborns. This innovative treatment helps to break down heme and inhibit bilirubin production, thereby reducing the necessity for phototherapy and exchange transfusions in affected infants. Through its targeted therapies, InfaCare aims to improve health outcomes for children facing critical health challenges.

Hemostasis involves in developing and marketing innovative technologies for the global medical industry. They manufacture advanced technology for the temporary treatment of moderate to severely bleeding wounds.

Stratatech Corporation is a regenerative medicine company focused on developing and commercializing cell-based and tissue-engineered skin substitutes for therapeutic and research purposes. Based in Madison, Wisconsin, the company specializes in creating human tissue substitutes using NIKS keratinocytes and related cells. Its notable products include StrataGraft skin tissue, which serves as a temporary wound cover that enhances healing by utilizing the patient’s own cells and prepares the wound bed for autografts. Additionally, the ExpressGraft skin tissue is a genetically engineered product that offers various levels of natural wound healing and antimicrobial properties. Founded in 2000, Stratatech aims to provide effective solutions for chronic, non-healing wounds, facilitating easier care for patients.

Therakos, Inc. specializes in providing extracorporeal photopheresis immune modulation therapy, primarily aimed at treating the skin manifestations of Cutaneous T-cell Lymphoma (CTCL) that do not respond to conventional treatments. The company's flagship product, the CELLEX System, integrates cell collection, photoactivation, and reinfusion technologies into a single, streamlined platform that facilitates single-operator management of the photopheresis process. This design minimizes the risks associated with infection and patient errors during reinfusion. Therakos' systems are utilized in various medical settings, including academic centers and hospitals, both in the United States and internationally. Founded in 1984 and based in West Chester, Pennsylvania, Therakos operates as a subsidiary of Mallinckrodt Public Limited Company, focusing on enhancing immunologic responses to improve patient outcomes.

Ikaria is a company focused on developing and delivering innovative therapeutics and interventions for critically ill patients. It operates as an integrated critical care provider, aiming to meet the unique and complex medical needs of this vulnerable population. By creating and commercializing advanced therapies, Ikaria seeks to be a vital partner for clinicians, offering essential support and care at crucial moments in patient treatment.

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the treatment of serious autoimmune and inflammatory disorders, particularly in the fields of neurology and nephrology. The company's primary product is H.P. Acthar Gel, an injectable medication approved by the U.S. Food and Drug Administration for various diseases and disorders. H.P. Acthar Gel is a highly purified preparation of the adrenal corticotropin hormone (ACTH) and is used to address significant unmet medical needs in patients. Additionally, Questcor markets Doral, a medication indicated for the treatment of insomnia characterized by difficulty in falling asleep and frequent awakenings. Through its focus on rare central nervous system and inflammatory disorders, Questcor aims to provide effective therapeutic options for patients facing challenging health conditions.

Cadence Pharmaceuticals is a biopharmaceutical company that specializes in the development and commercialization of proprietary product candidates for hospital use. The company focuses on in-licensing innovative therapies to enhance patient care. Its primary product is OFIRMEV, an intravenous formulation of acetaminophen designed for the management of pain and the reduction of fever in both adults and children. Cadence has made significant progress with OFIRMEV, having resubmitted a New Drug Application to the FDA, which has assigned a Prescription Drug User Fee Act action date for review.

CNS Therapeutics is a private company based in St. Paul, Minn. CNS Therapeutics develops and markets safe, high-quality pharmaceuticals for site-specific delivery to the central nervous system to treat neurological disorders and chronic pain. In addition to its first FDA-approved product, Gablofen, CNS Therapeutics is currently collaborating with U.S. and international scientific experts to develop and test new treatments for pain and Parkinson's disease.

Nellcor Puritan Bennett manufactures patient monitoring instruments and disposable supplies for use in surgery.